Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
05 mai 2022 16h01 HE
|
Oncternal Therapeutics
Global registrational Phase 3 study, ZILO-301, of zilovertamab in patients with MCL on track to be initiated in Q3 2022Presenting interim clinical data update from the ongoing Phase 1/2 clinical trial...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
02 mai 2022 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results
28 avr. 2022 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma
13 avr. 2022 08h30 HE
|
Oncternal Therapeutics
Discontinued enrollment of Phase 1/2 trial of ONCT-216 in Ewing sarcomaResources will be primarily reallocated to our zilovertamab global registrational Phase 3 study ZILO-301, which is expected to be...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
01 avr. 2022 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results
10 mars 2022 16h01 HE
|
Oncternal Therapeutics
Reached consensus with the FDA on the design and major details of the global Phase 3 Study ZILO-301 to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib, which is on...
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results
07 mars 2022 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
01 mars 2022 17h00 HE
|
Oncternal Therapeutics
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate Cancer
20 janv. 2022 16h05 HE
|
Oncternal Therapeutics
Session will include a discussion of the treatment landscape for Mantle Cell Lymphoma, including potential role of Zilovertamab, Oncternal’s ROR1 antibody ready for Phase 3 in R/R MCL, with recent FDA...
Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma
04 janv. 2022 16h01 HE
|
Oncternal Therapeutics
The company reached consensus with the FDA on the design and major details of the Phase 3 superiority Study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus...